Derfor forventes vildagliptin ikke at blive påvirket af samtidig administration af præparater, som er CYP 450- hæmmere og/ eller - induktorer.
Accordingly, the metabolic clearance of vildagliptin is not anticipated to be affected by co-medications that are CYP 9 450 inhibitors and/ or inducers.